Ofatumumab, other anti-CD20 monoclonal antibody, also in phase II for MS, and phase III for others autoimmune diseases.
Ofatumumab®, je antiCD20 monoklonalno antitelo, takođe u fazi II za MS, i fazi III za druge autoimune bolesti.